drugset / Trial / NCT07370909
Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis
Phase 3
Not yet recruiting
480 enrolled
Shanghai Longwood Biopharmaceuticals Co., Ltd.
Tigermed Consulting Co., Ltd · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This Phase 3, double-blind (sponsor-open), multicenter, placebo-controlled study aims to evaluate the efficacy and safety of oral LW402 tablets in patients with moderate to severe atopic dermatitis.
Timeline
- Start
- 2026-01-30
- Primary completion
- 2028-03-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LW402 | Unknown | 100 mg | Oral |
| Subject | LW402 | Unknown | 150 mg | Oral |